Aurobindo Pharma slumped 4.10% to Rs 1456.85 after the company informed that the manufacturing facility of its wholly owned subsidiary Eugia Pharma has received a warning letter from the US FDA.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
